Toronto, Ontario – March 29, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today the launch of the Theralase® Anti-Cancer Therapy (“ACT”) research centre located within the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Unity Health Toronto, effective April 1, 2022, relocating its research team from University Health Network (“UHN”), Toronto. The Li Ka Shing Knowledge Institute of St. Michael’s is home to leading researchers, educators and clinicians — dedicated professionals making new scientific discoveries, generating novel therapies, developing innovative training programs and helping translate knowledge into practice. The ACT research centre is a fully equipped laboratory dedicated exclusively to Theralase® ACT research and development as it advances towards commercialization with its lead … Read More

Toronto, Ontario – March 25, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that Urology San Antonio (“USA”) has received site Institutional Review Board (“IRB”) approval to commence a Pivotal Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) Clinical Study to enroll and treat patients with Bacillus Calmette Guerin(“BCG“)-Unresponsive Carcinoma In-Situ (“CIS“) or who are intolerant to BCG Therapy (“Study II“). This marks the sixth US Clinical Study Site (“CSS”) that has obtained site IRB approval through a central IRB. Theralase is at different stages with additional US clinical study sites that are expected to launch in 2Q21 and 3Q21. Urology San Antonio is the largest urology practice in South Texas with multiple locations offering care … Read More

Toronto, Ontario – February 24, 2021,Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that University of Wisconsin Health-Madison (“UWH”) has received site Institutional Review Board (“IRB”) approval to commence a pivotal Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) Clinical Study to enroll and treat patients with Bacillus Calmette Guerin(“BCG“)-Unresponsive Carcinoma In-Situ (“CIS“) or who are intolerant to BCG Therapy (“Study II“). This marks the fifth US clinical site that has successfully obtained site IRB approval through a central IRB. One additional US clinical study site is pending IRB site approval in 1Q2021. The Department of Urology at UWH is a leading academic program offering comprehensive multidisciplinary urologic care in conjunction with innovative research, teaching, … Read More

Toronto, Ontario – February 01, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, today is pleased to release the Company Quarterly Newsletter. The Newsletter provides updates on the previous quarter and progress on the Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) Clinical Study. The Newsletter can be found on the Company’s website www.theralase.com/quarterly-newsletters/ To receive future Newsletters, please contact info@theralase.com About Theralase® Technologies Inc. Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers. Additional information is available at www.theralase.com and www.sedar.com Forward-Looking Information This news release contains “forward-looking statements” which reflect the current expectations of management of the Company’s future growth, results of operations, performance and … Read More

Toronto, Ontario – January 27, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that Carolina Urologic Research Center (“CURC”) has received site Institutional Review Board (“IRB”) approval to commence a Pivotal Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) Clinical Study to enroll and treat patients with Bacillus Calmette Guerin(“BCG“)-Unresponsive Carcinoma In-Situ (“CIS“) or who are intolerant to BCG Therapy (“Study II“). This marks the fourth US clinical site that has obtained site IRB approval through a central IRB. There are 2 additional US clinical study sites that are expected to receive site IRB approval in 1Q2021. CURC has been recognized both nationally and internationally as one of the most progressive and respected clinical research sites in … Read More

Toronto, Ontario – January 25, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that MidLantic Urology (“MU”) has received site Institutional Review Board (“IRB”) approval to commence a Pivotal Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) Clinical Study to enroll and treat patients with Bacillus Calmette Guerin(“BCG“)-Unresponsive Carcinoma In-Situ (“CIS“) or who are intolerant to BCG Therapy (“Study II“). This marks the third US clinical site that has obtained both study level and site IRB approval through a central IRB. There are 3 pending US clinical study sites that are expected to receive site IRB approval in 1Q2021. MU, headquartered in Philadelphia, Pennsylvania, is a state-of-the-art urologic care center that embraces independent practice, innovation and … Read More

Toronto, Ontario – January 22, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations used to destroy various cancers, bacteria and viruses safely and effectively is pleased to announce that the Company has expanded its Intellectual Property (“IP”) portfolio. Theralase® has been notified by its legal council that there have been 3 recent decisions to grant a patent: specifically, 1) Russian – Metal-Glycoprotein Complexes 2) Indian – Metal-Glycoprotein Complexes and 3) Chinese – Multiwavelength Photo Dynamic Therapy (“PDT”). The patent’s entitled, “Metal-Glycoprotein Complexes and Their use as Chemotherapeutic Compounds” are critical in protecting Theralase®’s systemic and targeted anti-cancer therapies to allow PDCs and their associated drug formulations to be systemically injected to hunt and locate into cancer cells for various cancer conditions.  Once located in the cancer cells … Read More

Toronto, Ontario – January 20, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that Urology Associates P.C. (“UA”) has received site Institutional Review Board (“IRB”) approval to commence a pivotal phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) Clinical Study to enroll and treat patients with Bacillus Calmette Guerin(“BCG“)-Unresponsive Carcinoma In-Situ (“CIS“) or are intolerant to BCG Therapy (“Study II“). Theralase has central IRB approval to launch a number of US clinical sites, subject to local site IRB approval.  UA is the second site to receive both central and local site IRB approval.  There are 4 additional US clinical study sites that have received central IRB approval and are expected to receive local IRB approval in 1Q2021. Founded … Read More

Toronto, Ontario – January 19, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that Virginia Urology (“VU”) has received site Institutional Review Board (“IRB”) approval to commence a pivotal phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) Clinical Study to enroll and treat patients with Bacillus Calmette Guerin(“BCG“)-Unresponsive Carcinoma In-Situ (“CIS“) or are intolerant to BCG Therapy (“Study II“). Theralase has central IRB approval to launch a number of US clinical sites, subject to local site IRB approval.  VU is the first site to receive both central and local site IRB approval.  There are 5 additional US clinical study sites that have received central IRB approval and are expected to receive local IRB approval in 1Q2021. VU has … Read More

Toronto, Ontario – January 8, 2021, Theralase® Technologies Inc. (“Theralase” or “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs“) and their associated drug formulations intended to safely and effectively destroy various cancers, announces that the Company proposes to extend the expiry date of 4,095,157 share purchase warrants, all of which are exercisable at $0.50 per share (collectively, the “Warrants“). The Warrants were issued on January 9, 2019 pursuant to a private placement involving the issuance of 4,095,157 units of the Company. The Company proposes to extend the expiry date of the Warrants that remain outstanding from the original expiry date of January 9, 2021 to January 9, 2023. Theralase® Technologies Inc. (“Theralase” or “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs“) and their associated drug formulations intended to safely … Read More